Fig. 6From: UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activationUBE2C knockdown inhibits the proliferation of leukemia cells in vivo. (A) The graph shows the subcutaneous tumor volume in nude mice after 4, 8, 12, 16, 20, 24, 28, 32, and 36 days. (B) The graph presents the tumor mass in nude mice treated with sh-UBE2C. (C) The images show the immunohistochemical detection of expression levels of UBE2C, KI-67, and cleaved-caspase 3 in tumor tissues. *** signifies P < 0.001 compared with the sh-NC groupBack to article page